Spots Global Cancer Trial Database for plasma cell leukemia

Every month we try and update this database with for plasma cell leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	NCT03389347	Plasma Cell Leu... Recurrent Multi... Refractory Mult...	Biospecimen Col... High Throughput... Laboratory Biom...	18 Years -	University of Washington
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma	NCT00821249	Multiple Myelom... Plasma Cell Leu...	ARRY-520, KSP(E... Filgrastim, gra... Dexamethasone, ...	18 Years -	Pfizer
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma	NCT02504359	Plasma Cell Leu... Recurrent Plasm...	Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus	18 Years - 65 Years	OHSU Knight Cancer Institute
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH	NCT05283993	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm...	No intervention	-	Peking University First Hospital
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH	NCT05283993	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm...	No intervention	-	Peking University First Hospital
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia	NCT03591744	Plasma Cell Leu...	Bortezomib Daratumumab Dexamethasone Lenalidomide Pegylated Lipos...	18 Years -	City of Hope Medical Center
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma	NCT02315157	Multiple Myelom... Plasma Cell Leu...	Bendamustine	18 Years - 80 Years	Thomas Jefferson University
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	NCT01372540	Plasma Cell Leu... Recurrent Plasm... Refractory Plas...	Carfilzomib Filanesib Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Registry for Adults With Plasma Cell Disorders (PCD's)	NCT03717844	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu...		18 Years -	UNC Lineberger Comprehensive Cancer Center
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia	NCT01328236	Plasma Cell Leu... Multiple Myelom...	Bortezomib Liposome doxoru... Dexamethasone	18 Years - 75 Years	Clinical Service, China
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	NCT01008462	B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac...	Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01729091	Plasma Cell Leu... Plasma Cell Mye...	Autologous Hema... Elotuzumab Laboratory Biom... Lenalidomide Melphalan Natural Killer ... Umbilical Cord ...	18 Years - 75 Years	M.D. Anderson Cancer Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia	NCT05822037	Multiple Myelom... Plasma Cell Leu...	CT0594CP	18 Years - 75 Years	The First Affiliated Hospital of Soochow University
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry	NCT05556928	Multiple Myelom... Amyloidosis Plasma Cell Leu...		50 Years -	University of Alabama at Birmingham
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia	NCT05870917	Plasma Cell Leu...	anti-BCMA CAR-T	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma	NCT01163357	Autologous Hema... Loss of Chromos... Plasma Cell Leu... Recurrent Plasm... Refractory Plas...	bortezomib fludarabine pho... melphalan total marrow ir... tacrolimus sirolimus peripheral bloo... laboratory biom...	18 Years - 70 Years	City of Hope Medical Center
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	NCT05823571	Leukemia, Acute Myelodysplastic... Myelomonocytic ... T-cell Prolymph... CML Myeloproliferat... Multiple Myelom... Plasma Cell Leu...	Itacitinib	60 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma	NCT02315157	Multiple Myelom... Plasma Cell Leu...	Bendamustine	18 Years - 80 Years	Thomas Jefferson University
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)	NCT01435720	Multiple Myelom... Multiple Myelom... Mantle Cell Lym... Diffuse Large B... Other B Cell Ly... Plasma Cell Leu...	SNS01-T SNS01-T SNS01-T SNS01-T	18 Years -	Senesco Technologies, Inc.
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma	NCT00821249	Multiple Myelom... Plasma Cell Leu...	ARRY-520, KSP(E... Filgrastim, gra... Dexamethasone, ...	18 Years -	Pfizer
Expanded Access to Venetoclax	NCT03123029	Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu...	Venetoclax	-	AbbVie
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients	NCT04008888	Multiple Myelom... Plasma Cell Leu... Extramedullary ... Loss of Chromos... t(14;16) t(4;14) T(14;20) 1Q21 Amplificat... Complex Karyoty...	Allogeneic Hema... Autologous Hema... Melphalan Given... Fludarabine Inj... PI and dexameth... PI+IMids+Dexame...	18 Years - 60 Years	Institute of Hematology & Blood Diseases Hospital, China
Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation	NCT05054478	Plasma Cell Leu...	Daratumumab	18 Years - 69 Years	Assistance Publique - Hôpitaux de Paris
European Myeloma Network (EMN) Sample Project	NCT06237803	Multiple Myelom... Smoldering Mult... Plasma Cell Leu... Extramedullary ... MGUS	storage of biol...	18 Years -	Stichting European Myeloma Network
Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia	NCT01553357	Primary Plasma ...	Lenalidomide, d...	18 Years -	IRCCS Centro di Riferimento Oncologico della Basilicata
European Myeloma Network (EMN) Sample Project	NCT06237803	Multiple Myelom... Smoldering Mult... Plasma Cell Leu... Extramedullary ... MGUS	storage of biol...	18 Years -	Stichting European Myeloma Network
Expanded Access to Venetoclax	NCT03123029	Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu...	Venetoclax	-	AbbVie
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma	NCT02506959	Plasma Cell Leu... Plasmacytoma Recurrent Plasm... Refractory Plas...	Autologous Hema... Busulfan Gemcitabine Hyd... Laboratory Biom... Melphalan Panobinostat Peripheral Bloo... Pharmacological...	18 Years - 65 Years	M.D. Anderson Cancer Center
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies	NCT02556931	Myelodysplastic... Chronic Myelomo... Small Lymphocyt... Chronic Lymphoc... Prolymphocytic ... Chronic Myeloid... Chronic Myelopr... Multiple Myelom... Plasma Cell Neo... Plasma Cell Dys... Myelofibrosis Polycythemia Ve... Essential Throm... Plasma Cell Leu...	Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate m...	-	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia	NCT03591744	Plasma Cell Leu...	Bortezomib Daratumumab Dexamethasone Lenalidomide Pegylated Lipos...	18 Years -	City of Hope Medical Center
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma	NCT01163357	Autologous Hema... Loss of Chromos... Plasma Cell Leu... Recurrent Plasm... Refractory Plas...	bortezomib fludarabine pho... melphalan total marrow ir... tacrolimus sirolimus peripheral bloo... laboratory biom...	18 Years - 70 Years	City of Hope Medical Center
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	NCT01372540	Plasma Cell Leu... Recurrent Plasm... Refractory Plas...	Carfilzomib Filanesib Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia	NCT01328236	Plasma Cell Leu... Multiple Myelom...	Bortezomib Liposome doxoru... Dexamethasone	18 Years - 75 Years	Clinical Service, China
Registry for Adults With Plasma Cell Disorders (PCD's)	NCT03717844	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu...		18 Years -	UNC Lineberger Comprehensive Cancer Center
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry	NCT05556928	Multiple Myelom... Amyloidosis Plasma Cell Leu...		50 Years -	University of Alabama at Birmingham
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma	NCT02506959	Plasma Cell Leu... Plasmacytoma Recurrent Plasm... Refractory Plas...	Autologous Hema... Busulfan Gemcitabine Hyd... Laboratory Biom... Melphalan Panobinostat Peripheral Bloo... Pharmacological...	18 Years - 65 Years	M.D. Anderson Cancer Center
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia	NCT05870917	Plasma Cell Leu...	anti-BCMA CAR-T	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Plasma Cell Leu... Myelofibrosis Myelodysplasia Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large B... Lymphoblastic L... Burkitt's Lymph... Non-Hodgkin Lym... Multiple Myelom...	Fludarabine Cyclophosphamid... Total Body Irra... Cyclosporine A Mycophenylate m... Umbilical cord ...	- 55 Years	Masonic Cancer Center, University of Minnesota
Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia	NCT01553357	Primary Plasma ...	Lenalidomide, d...	18 Years -	IRCCS Centro di Riferimento Oncologico della Basilicata
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Plasma Cell Leu... Myelofibrosis Myelodysplasia Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large B... Lymphoblastic L... Burkitt's Lymph... Non-Hodgkin Lym... Multiple Myelom...	Fludarabine Cyclophosphamid... Total Body Irra... Cyclosporine A Mycophenylate m... Umbilical cord ...	- 55 Years	Masonic Cancer Center, University of Minnesota
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	NCT05823571	Leukemia, Acute Myelodysplastic... Myelomonocytic ... T-cell Prolymph... CML Myeloproliferat... Multiple Myelom... Plasma Cell Leu...	Itacitinib	60 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allo HSCT Using RIC and PTCy for Hematological Diseases	NCT05805605	Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis	Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M...	- 75 Years	Masonic Cancer Center, University of Minnesota

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: